CordenPharma Purification solutions across our network span crystallization, preparative chromatography, Supercritical Fluid Chromatography (SFC), and Tangential Flow Filtration (TFF). All technology transfers follow a risk-based, Quality by Design (QbD) approach, with small-scale trials and Design of Experiments (DoE) ensuring reproducible, compliant scale-up. By combining deep expertise, expansive capacity, and strategically located facilities across Switzerland, France, Italy and the US, we help innovators advance their non-potent and highly potent small molecule drug substance efficiently and reliably, delivering the supply and support needed to bring medicines from discovery to patients. Bringing molecule to market: Small molecule and highly potent platform drug products In 2025, CordenPharma has expanded Small Molecule and Highly Potent Drug Product services to meet growing global demand. Our Plankstadt (DE) facility now features a medium-scale Oral Solid Dosage (OSD) line capable of handling both non-potent and highly potent compounds with OEL levels as low as <0.05 µg/m³. This line bridges small- and large-scale capacities, supporting early-stage development as well as clinical and commercial manufacturing, addressing formulation challenges, enhancing bioavailability, and enabling production of complex OSD products. Flexible dosage forms such as minitablets and precision capsule filling facilitate adjustable dosing and modified release profiles, ensuring safe, accurate, and efficient delivery from first-in-human studies to commercial supply. In Lisbon (PT), new roller compactors and tablet coaters enhance formulation flexibility, while additional oral liquid filling lines at Fribourg (CH) provide efficient supply for diverse dosage forms. Both Lisbon and Fribourg have extensive primary and secondary packaging capacities to provide full, end-to-end manufacturing and distribution capability with experience supplying to over 70 countries worldwide. Selecting the right partner for OSD drug product development and manufacturing is critical. CordenPharma accompanies your products across the entire lifecycle, from early phase formulation development and clinical supply through latestage registration, validation, and commercial manufacturing. We handle APIs with OELs down to the picogram per cubic meter level and support both small molecules and peptides. Our structured approach incorporates biopharmaceutic principles for early phase screening, compatibility assessments, and scalable process development. 17 (CordenPharma Photo) Small Molecule API manufacturing facility in CordenPharma Chenôve (FR). DAILY NEWS CPHI 2025 FRANKFURT DAY 1 | 28th October 2025
RkJQdWJsaXNoZXIy MjY2OTA4MA==